Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott Laboratories : BECOMES FIRST ANCHOR SPONSOR OF AMERICAN DIABETES ASSOCIATION'S HEALTH EQUITY NOW INITIATIVE TO ADVANCE ACCESS TO CARE AND TECHNOLOGY FOR PEOPLE WITH DIABETES

11/19/2020 | 08:45am EST

Today, Abbott (NYSE: ABT) and the American Diabetes Association (ADA) announced that Abbott has become the first anchor sponsor of the Health Equity Now (HEN) platform to address health disparities for people with diabetes.

Abbott's sponsorship includes a three-year, $5 million commitment to support the ADA's advocacy and community-driven projects aimed at removing barriers to care and providing greater access to the latest medical technologies and health resources for underserved diabetes populations.

'It's important that people with diabetes in the U.S. have access to the latest innovations to effectively manage their condition and help them thrive,' said Tracey D. Brown, chief executive officer of the American Diabetes Association. 'It is time to tear down the systemic barriers that separate us based on zip code, income level, education, color and gender, and it's time that we demand health equity now.'

Data show that compared to white adults, the risk of being diagnosed with diabetes is higher among Black Americans (77%), Latinos (66%), and Asian Americans (18%).1 With 50% of low-income Americans with diabetes having lost some or all income during the pandemic,2 COVID-19 has brought greater attention to the large gaps in the U.S. healthcare system, shining a light on the health and economic disparities faced by Americans in underserved communities.

To address these health inequities, the ADA created the Health Equity Bill of Rights, which includes a core right for all to access the latest medical advances. Abbott will support the ADA's advocacy efforts to tear down barriers that limit access to high-quality medical technologies, including continuous glucose monitoring (CGM) advancements, among others.

'No matter someone's race, income level or background, quality care and life-changing technologies should be affordable and broadly accessible to all people living with diabetes,' said Jared Watkin, senior vice president, Diabetes Care, Abbott. 'Abbott is proud to support the ADA's goal to work toward health equity and to advance access to the latest technologies for people with diabetes, helping them lead healthier, fuller lives with dignity.'

Another primary focus of Abbott's sponsorship will drive sustained community engagement through local programs and initiatives to help improve diabetes-related health outcomes. With Abbott's support, the ADA will immediately begin work to bring together experts and collaborate with underserved communities to develop key program outreach models that include public health education, professional education and training and other community services that will be rolled out in 2021.

About the American Diabetes Association:

Every day more than 4,000 people are newly diagnosed with diabetes in America. More than 122 million Americans have diabetes or prediabetes and are striving to manage their lives while living with the disease. The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 80 years the ADA has been driving discovery and research to treat, manage and prevent diabetes, while working relentlessly for a cure. We help people with diabetes thrive by fighting for their rights and developing programs, advocacy and education designed to improve their quality of life. Diabetes has brought us together. What we do next will make us Connected for Life.

About Abbott

As part of our purpose to help people live fuller lives through better health, Abbott is committed to advancing health equity, working side-by-side with the communities we serve to address health disparities and tackle barriers to health. This includes efforts across our business and in partnership with others to expand access to technology, quality care and nutrition, and to advance STEM and health education to inspire a diverse and innovative next generation. Looking ahead, Abbott will further extend these efforts with the launch of its 2030 sustainability strategy and plan later this year, with forward-looking targets to build a stronger, more sustainable Abbott that better serves the many people who depend on us.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Ying-Ying Meng et al. Racial and Ethnic Disparities in Diabetes Care and Impact of Vendor-Based Disease Management Programs. Diabetes Care, May 2016.

Diabetes and COVID-19: New Data Quantifies Extraordinary Challenges Faced by Americans with Diabetes During Pandemic. Survey by dQ&A and The American Diabetes Association. July 2020.

Contact:

Tel: +1 (202) 213-5129

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ABBOTT LABORATORIES
10:11aABBOTT LABORATORIES' : Fourth-Quarter Sales Jump as COVID-19 Testing Demand Bols..
MT
09:42aGLOBAL MARKETS LIVE: Boeing, Microsoft, AMD…
09:20aSECTOR UPDATE : Health Care Stocks Down in Wednesday's Premarket Trading
MT
09:08aSECTOR UPDATE : Health Care
MT
08:13aABBOTT LABORATORIES : Sees Larger-Than-Expected 2021 Profit
DJ
08:06aABBOTT LABORATORIES : Posts Profit Growth on Covid-19 Testing Activity
DJ
08:05aABBOTT LABORATORIES : Posts Higher Earnings, Revenue in Q4
MT
07:46aABBOTT : 4Q Earnings Snapshot
AQ
07:43aABBOTT LABORATORIES : Results of Operations and Financial Condition, Financial S..
AQ
07:34aABBOTT LABORATORIES : Earnings Flash (ABT) ABBOTT Posts Q4 EPS $1.45, vs. Street..
MT
More news
Financials (USD)
Sales 2020 33 854 M - -
Net income 2020 4 415 M - -
Net Debt 2020 11 794 M - -
P/E ratio 2020 46,9x
Yield 2020 1,26%
Capitalization 197 B 197 B -
EV / Sales 2020 6,16x
EV / Sales 2021 5,34x
Nbr of Employees 107 000
Free-Float 88,9%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 120,53 $
Last Close Price 114,73 $
Spread / Highest target 26,4%
Spread / Average Target 5,05%
Spread / Lowest Target -28,5%
EPS Revisions
Managers and Directors
NameTitle
Robert B. Ford President, CEO, Chief Operating Officer & Director
Miles D. White Executive Chairman
Robert E. Funck Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES4.79%196 578
MEDTRONIC PLC-0.33%157 148
BECTON, DICKINSON AND COMPANY3.25%75 142
HOYA CORPORATION-3.92%48 957
ALIGN TECHNOLOGY, INC.0.13%42 193
BAXTER INTERNATIONAL INC.0.71%41 279